Stroke is one of those diseases that do not give notice and pounce and causing much injure to temporary or permanent in any case the damage caused by a stroke can be substantial and that is why we must be practical with avoidance and treatment right. Today we see a new molecule exposed in the laboratory that serves to defeat the stroke. The molecule in question is called titillate and was presented at the European assembly of Cardiology (ESC) being held in Barcelona. This drug completely revolutionizes therapy for heart patients and is the result of a very wide research that has involved 18,113 patients in 44 countries counting Italy. This molecule has proved very effective really reduced the cases of stroke by 34% and risk of death by 12%.

A trial fibrillation is a temporary paralysis of the atrium because a stagnation of blood clotting that may be small. When they enter general circulation should be to block the vessels and when the obstacle occurs in the brain it comes to stroke.Patients suffering from atrial fibrillation have about a 7 times as likely to be pretentious by a stroke. Classical treatment are aimed at making the blood more fluid and so are not shaped during the clotting stagnation but have easy heart patients because they can not do physical movement they must follow specific diet and feel constant blood tests. With the new molecule there will be no contraindications, the dose are fixed, two pills a day, and there is no need for continuous monitor.